Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Core Insights - Kodiak Sciences Inc. successfully closed a public offering of 8,000,000 shares at a price of $23.00 per share, generating approximately $184 million in gross proceeds before expenses [1][3]. Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on developing transformative therapeutics for retinal diseases, utilizing its proprietary ABC® Platform for next-generation retinal medicines [5]. Financial Position - The completion of the public offering strengthens Kodiak's financial position as it prepares for important Phase 3 topline readouts for its late-stage clinical assets: KSI-101, KSI-501, and tarcocimab [3]. Clinical Programs - Kodiak is advancing three late-stage clinical programs, with tarcocimab and KSI-501 in two BLA-facing Phase 3 studies for retinal vascular diseases, and KSI-101 being explored in two Phase 3 studies for Macular Edema Secondary to Inflammation (MESI) [5]. Underwriters - The offering was managed by J.P. Morgan, Jefferies, Evercore ISI, and UBS Investment Bank as joint book-running managers [2].